Last reviewed · How we verify
Sucroferric Oxyhydroxide Chewable Tablet
Sucroferric Oxyhydroxide Chewable Tablet is a Phosphate binder Small molecule drug developed by University of Colorado, Denver. It is currently FDA-approved for Hyperphosphatemia in patients with chronic kidney disease on dialysis, Hyperphosphatemia in patients with chronic kidney disease not on dialysis. Also known as: Velphoro.
Sucroferric oxyhydroxide binds phosphate in the gastrointestinal tract to reduce serum phosphate levels in patients with chronic kidney disease.
Sucroferric oxyhydroxide is a small molecule that acts as a phosphate sequestering agent. It is used to treat conditions such as hyperphosphatemia and hypoalbuminemia in patients with chronic kidney disease requiring chronic dialysis.
At a glance
| Generic name | Sucroferric Oxyhydroxide Chewable Tablet |
|---|---|
| Also known as | Velphoro |
| Sponsor | University of Colorado, Denver |
| Drug class | Phosphate binder |
| Target | Dietary phosphate (non-receptor mechanism) |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | FDA-approved |
Mechanism of action
This iron-based phosphate binder works by forming insoluble complexes with dietary phosphate in the GI lumen, preventing phosphate absorption and lowering serum phosphate concentrations. It is particularly useful in dialysis patients and those with chronic kidney disease who need to control hyperphosphatemia. The chewable tablet formulation allows for flexible dosing and improved patient compliance.
Approved indications
- Hyperphosphatemia in patients with chronic kidney disease on dialysis
- Hyperphosphatemia in patients with chronic kidney disease not on dialysis
Common side effects
- Discolored (dark) stools
- Nausea
- Constipation
- Abdominal pain
Key clinical trials
- Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders (PHASE4)
- Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients (PHASE4)
- PA21 Safety and Efficacy in Adult Chinese Subjects (PHASE3)
- A Study to Investigate the Safety and Efficacy of PA21 (Velphoro®) and Calcium Acetate (Phoslyra®) in Paediatric and Adolescent Chronic Kidney Disease (CKD) Patients With Hyperphosphataemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sucroferric Oxyhydroxide Chewable Tablet CI brief — competitive landscape report
- Sucroferric Oxyhydroxide Chewable Tablet updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI
Frequently asked questions about Sucroferric Oxyhydroxide Chewable Tablet
What is Sucroferric Oxyhydroxide Chewable Tablet?
How does Sucroferric Oxyhydroxide Chewable Tablet work?
What is Sucroferric Oxyhydroxide Chewable Tablet used for?
Who makes Sucroferric Oxyhydroxide Chewable Tablet?
Is Sucroferric Oxyhydroxide Chewable Tablet also known as anything else?
What drug class is Sucroferric Oxyhydroxide Chewable Tablet in?
What development phase is Sucroferric Oxyhydroxide Chewable Tablet in?
What are the side effects of Sucroferric Oxyhydroxide Chewable Tablet?
What does Sucroferric Oxyhydroxide Chewable Tablet target?
Related
- Drug class: All Phosphate binder drugs
- Target: All drugs targeting Dietary phosphate (non-receptor mechanism)
- Manufacturer: University of Colorado, Denver — full pipeline
- Therapeutic area: All drugs in Nephrology
- Indication: Drugs for Hyperphosphatemia in patients with chronic kidney disease on dialysis
- Indication: Drugs for Hyperphosphatemia in patients with chronic kidney disease not on dialysis
- Also known as: Velphoro
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing